Lonza Group AG LONN:SIX; LO3:FSE; LZAGF:OTCPK

Notable Quotes

"DRIO is developing a very interesting approach to diagnostics at the level of data capture." (12/5/13) LabStyle Innovations Corp. - The Life Sciences Report Interview with Ram Selvaraju More�>

"CPRX has a few programs in indications that are less crowded and do not have many successful treatment options." (11/26/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Michael Hay More�>

"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More�>

"CYTX's ADRC product has been approved for breast reconstruction in Europe." (11/26/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Michael Hay More�>

"We expect FDA approval in the near term�likely by the end of the year�for OCLS' Microcyn Hydrogel device." (11/26/13) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Jocelyn August More�>

Companies

Lonza Group AG

TICKER: LONN:SIX; LO3:FSE; LZAGF:OTCPK

Would you like more information on this company?

First Name *

Last Name

Email *

Phone

* Required

In addition, I would like to receive The Life Sciences Report Newsletter

Fact sheets, annual reports, webinars, CEO interviews and more, may be available for this company. Fill out this form and your contact information will be shared with this company to provide you with additional information.